Sarah advises medical products companies developing and manufacturing pharmaceuticals, biologics, and medical devices on issues where FDA regulatory and compliance matters intersect with strategic business decision-making. She specifically focuses on providing FDA regulatory and compliance counsel to medical products clients on a variety of matters, including Good Clinical Practice and clinical trials, pharmacovigilance, medical communications and health care economic information, Good Manufacturing Practice (drugs and medical devices), advertising and promotion, patient support programs, and ClinicalTrials.gov registration and reporting. She has also written and spoken extensively on clinical trial modernization and diversity, in addition to the implications of the recent Food and Drug Omnibus Reform Act (FDORA) and current draft FDA guidance.
Experience
Representative matters
Recognitions
- Named to list of Top 40 Under 40 in Texas by The National Black Lawyers (2021- 2023)
- Selected to participate in the Leadership Council on Legal Diversity Pathfinders program (2021)
- Selected to Thomson Reuters’ “Super Lawyers - Rising Stars” List (2023)
Credentials
Education
- University of Virginia School of Law, 2014, J.D.
- George Mason University, 2009, M.S.
- George Mason University, 2006, B.S.
Professional admissions & qualifications
- Texas
Professional affiliations
- Member of the Food and Drug Law Institute (FDLI)
- Healthcare Businesswomen’s Association
- Member of the Board of Trustees at The Shlenker School
